ImmuPharma (LON:IMM) Issues Quarterly Earnings Results

ImmuPharma (LON:IMM) announced its earnings results on Tuesday. The company reported GBX (0.84) earnings per share (EPS) for the quarter, Digital Look Earnings reports. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 353.21%.

ImmuPharma Stock Performance

Shares of IMM stock opened at GBX 3.45 on Wednesday. ImmuPharma has a 52-week low of GBX 3.02 and a 52-week high of GBX 16. The firm has a market capitalization of £21.52 million, a P/E ratio of -9.32 and a beta of 3.01. The stock has a 50 day moving average price of GBX 3.87 and a 200 day moving average price of GBX 4.50.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.